azd4144
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 7, 2023 (NCT06122714)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07215702 | Phase 2 | Dec 2, 2025 | AstraZeneca |
| NCT06948006 | Phase 1 | Apr 23, 2025 | AstraZeneca, Parexel |
| NCT06942923 | Phase 1 | Apr 22, 2025 | AstraZeneca |
| NCT06925854 | Phase 1 | Apr 17, 2025 | AstraZeneca |
| NCT06675175 | Phase 1 | Nov 27, 2024 | AstraZeneca |
| NCT06693765 | Phase 1 | Nov 18, 2024 | AstraZeneca, Parexel |
| NCT06491550 | Phase 1 | Jul 15, 2024 | AstraZeneca |
| NCT06122714 | Phase 1 | Nov 7, 2023 | AstraZeneca, Parexel |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 8 | 8 | 2 | 2023 |
| Parexel | For profit | 3 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1